Synbio International, Inc. (OTC: SYIN) has announced a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize the latter's proprietary nutraceutical formulations across the United States and Canada. The agreement covers MD PHD Wellness' flagship anti-anxiety nutraceutical, which will be marketed under Synbio's Healing Force™ brand, and establishes a framework for evaluating and commercializing additional wellness products over time.
This partnership provides Synbio with immediate access to proprietary nutraceutical products without the time and cost associated with in-house development, significantly accelerating the company's path to revenue generation. Under the terms, MD PHD Wellness will manage product development, manufacturing, quality assurance, and supply chain, while Synbio will handle branding, marketing, sales, and distribution. Profits from product sales will be shared after recovery of approved costs.
Claudio Solitario, CEO of Synbio International, described the agreement as a "transformational milestone" that combines MD PHD's expertise with Synbio's commercialization capabilities. "It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time," he said, emphasizing the focus on building brands and generating sales to create shareholder value.
The global nutraceutical market is expanding rapidly, and this move positions Synbio to participate through a growing portfolio of scientifically developed products. Simultaneously, the company continues to advance its longer-term AI-driven healthcare technologies, including a mental health screening software that uses facial analysis.
MD PHD Wellness brings significant scientific leadership to the partnership. Co-founded by Dr. Robert Lawrence, a physician and scientist with Ph.D.s in Nuclear Physics and Biomedical Engineering, and Dr. David Anderson, an experienced physician and researcher, the company has developed formulations backed by rigorous research. Dr. Anderson's background includes serving as a Research Physician at a prominent New York university, where he participated in the scientific validation of therapeutics and nutraceuticals.
This agreement aligns with Synbio's broader strategy of building a diversified healthcare company, pairing near-term revenue from commercial wellness products with long-term value from its AI technologies. The dual-track approach is designed to provide multiple avenues for growth and establish recurring revenue to support continued innovation.
For more information about Synbio International and its strategic initiatives, visit their website at www.synbiointl.com.
